Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of Black Diamond Therapeutics Inc (NASDAQ: BDTX) was $1.91 for the day, down -4.98% from the previous closing price of $2.01. In other words, the price has decreased by -$4.98 from its previous closing price. On the day, 0.52 million shares were traded.
Ratios:
Our analysis of BDTX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.55 and its Current Ratio is at 5.55. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.20.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Raymond James on July 31, 2024, initiated with a Outperform rating and assigned the stock a target price of $20.
Stifel Upgraded its Hold to Buy on June 30, 2023, whereas the target price for the stock was revised from $2 to $10.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 28 ’24 when Versant Venture Capital VI, L. sold 221,600 shares for $6.32 per share. The transaction valued at 1,400,556 led to the insider holds 3,726,341 shares of the business.
David Epstein bought 50,000 shares of BDTX for $310,000 on Jul 31 ’24. On Jul 26 ’24, another insider, David Epstein, who serves as the Former Employee of the company, bought 50,000 shares for $6.20 each.
Stock Price History:
Over the past 52 weeks, BDTX has reached a high of $7.66, while it has fallen to a 52-week low of $1.90. The 50-Day Moving Average of the stock is -15.96%, while the 200-Day Moving Average is calculated to be -51.37%.
Shares Statistics:
A total of 56.52M shares are outstanding, with a floating share count of 43.10M. Insiders hold about 23.83% of the company’s shares, while institutions hold 75.16% stake in the company.
Earnings Estimates
The stock of Black Diamond Therapeutics Inc (BDTX) is currently being evaluated by 6.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.33, with high estimates of -$0.2 and low estimates of -$0.44.
Analysts are recommending an EPS of between -$1.04 and -$1.34 for the fiscal current year, implying an average EPS of -$1.27. EPS for the following year is -$1.25, with 6.0 analysts recommending between -$0.68 and -$1.93.
